|
A Study of DS-3939a in Participants With Solid Tumors
RECRUITINGPhase 1/2Sponsored by Daiichi Sankyo
Actively Recruiting
PhasePhase 1/2
SponsorDaiichi Sankyo
Started2026-10-13
Est. completion2030-07-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →
NCT07739966
Summary
The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: 1. Sign and date the Main Trial informed consent form (ICF), prior to the start of any trial-specific procedures. 2. Adults greater than or equal to (≥)18 years of age at the time the Main Trial ICF is signed (follow local regulatory requirements if the legal age of consent for trial participation is \>18 years old). 3. Histologically documented Stage IIIB, IIIC disease who is not candidate for surgical resection or definitive chemoradiation, or Stage IV NSQ NSCLC. 4. Has a left ventricular ejection fraction (LVEF) ≥50 percent (%) by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days of the first trial intervention. 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 assessed no more than 14 days prior to initiation of trial interventions. 6. Has adequate organ function. 7. Participants must have measurable disease by investigator assessment according to RECIST v1.1. Additional Inclusion Criteria for Substudy 1: 1\. Participants must not have received prior systemic therapy for locally advanced unresectable or metastatic NSCLC. Additional Inclusion Criteria for Substudy 2: 1. Participants with AGA (excluding EGFR mutation): Participants have been previously treated with targeted therapy for the AGA and platinum-based chemotherapy for the advanced disease setting. 2. Participants without AGA: Participants have been previously treated with platinum-based chemotherapy and anti-programmed death-1 (anti-PD-1)/programmed death-ligand 1 (PD-L1) antibody 3. Part 2 only: Participants must have received only 1 or 2 prior lines of anticancer therapy for the advanced disease setting. Exclusion Criteria: 1. Prior systemic anticancer therapy targeting MUC1 or TA-MUC1. 2. Prior systemic anticancer therapy with topoisomerase 1 inhibitor or topoisomerase 1 inhibitor-based antibody-drug conjugate (ADCs) (e.g., datopotamab deruxtexan and Sacituzumab govitecan). 3. Has spinal cord compression or clinically active central nervous system (CNS) metastases. 4. Has multiple primary malignancies. 5. Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening 6. Has active or uncontrolled human immunodeficiency virus (HIV) infection. 7. Has active or uncontrolled hepatitis B virus (HBV)/hepatitis C virus (HCV) infection. 8. Any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event. 9. Current participation in other therapeutic investigational procedures, except for participation in long term survival follow-up (LTSFU) without any investigational treatment.
Conditions5
CancerLocally Advanced Non-Small Cell Lung CancerLung CancerMetastatic Non-Small Cell Lung CancerSolid Tumor
Interventions5
Locations7 sites
Highlands Oncology Group (Hog) - Fayetteville
UCLA Health
Lifespan Cancer Institute - Rhode Island Hospital
Find trials near these locations
Cancer trials in Los AngelesCancer trials in TampaCancer trials in PortlandCancer trials in HoustonLung Cancer trials in Los AngelesLung Cancer trials in TampaLung Cancer trials in PortlandLung Cancer trials in HoustonAll trials in ArkansasAll trials in CaliforniaAll trials in FloridaAll trials in OregonAll trials in Rhode IslandAll trials in TexasAll trials in Virginia
Related trials
- A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors — Daiichi Sankyo
- First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors — Daiichi Sankyo
- A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors — The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC — CuraCell TX AB
- A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors — Aptabio Therapeutics, Inc.
- A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial) — Taipei Veterans General Hospital, Taiwan
- A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma. — Universitair Ziekenhuis Brussel
- A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1/2
SponsorDaiichi Sankyo
Started2026-10-13
Est. completion2030-07-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →
NCT07739966